Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Saturday. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Up 250.3 %

NASDAQ:ADXS opened at $0.11 on Friday. Ayala Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $0.97. The company has a fifty day simple moving average of $0.03 and a two-hundred day simple moving average of $0.03. The company has a market cap of $4.48 million, a price-to-earnings ratio of -0.01 and a beta of 1.63.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.